Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience

Karabulut K., Özbalcı G. S., Kesicioglu T., Tarım İ. A., Lap G., Polat A., ...More

ANNALS OF SURGICAL TREATMENT AND RESEARCH, no.2, pp.61-65, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2014
  • Doi Number: 10.4174/astr.2014.87.2.61
  • Journal Name: ANNALS OF SURGICAL TREATMENT AND RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.61-65
  • Keywords: Albendazole, Hepatic echinococcosis, Recurrence, CYSTIC ECHINOCOCCOSIS, HEPATOBILIARY SYSTEM, LIVER HYDATIDOSIS, DISEASE, MEBENDAZOLE, THERAPY, PHARMACOKINETICS, RISK
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Purpose: The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis. Methods: One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12-15 mg/kg/day. The ALB treatment was started 13.27 +/- 14.34 days before the surgery, and it was continued for 4.39 +/- 3.11 months postoperatively. A total of 1.7 mu g/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 +/- 51.56 months. Results: Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively. Conclusion: Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.